Kunena :: Тема: Posted by Rose on 29.11.2016 15:20:37: mekanisme kerja erlotinib (1/2)

Навигация: Главная Форум Главный раздел Сообщество базовых площадокPosted by Rose on 29.11.2016 15:20:37: mekanisme kerja erlotinib

Добро пожаловать, Гость

Форум

Главный раздел

Сообщество базовых площадок

Posted by Rose on 29.11.2016 15:20:37: mekanisme kerja erlotinib

Страница:
1
2

ТЕМА: Posted by Rose on 29.11.2016 15:20:37: mekanisme kerja erlotinib

Posted by Rose on 29.11.2016 15:20:37: mekanisme kerja erlotinib 7 года 5 мес. назад #916

akipk

High Quality - Low Cost Anti-Cancer Drugs

*
Erlotinib hydrochloride CAS 183319-69-9 GMP manufacture
a) slurrying erlotinib free base in water; and
ZHANG Yu-jia;XIANG Li;CHEN Shao-hua;ZHENG Wen-sheng;Institute of Materia Medica,Chinese Academy of Medical Sciences& Peking Union Medical College,Beijing City Key Laboratory of Drug Delivery Technology and Novel Formulations;;Content Determination of Erlotinib Tablets by HPLC with Gradient Elution [J];China Pharmacy;2014-45
ubsk.com.ua/ru/forum/skrin-ka-propozitsi...-30-erlotinib-magyar
Tarceva maximum tolerated dose in mg
There it was: the reason why tarceva worked better in never smokers. But in fact that was not the whole story. Tarceva, like many other drugs, is broken down in the body by an enzyme group called CYP 1A1/1A2. Enzymes are proteins that help to break down and digest our food, but enzymes can break down and digest many other things as well. The products in inhaled tobacco smoke stimulate this enzyme CYP, which then further breaks down tarceva in the body before it has a chance to work.
11. Carser JE, Summers YJ. Trichomegaly of the eyelashes after treatment with erlotinib in non-small cell lung cancer. J Thorac Oncol. 2006;1:1040-1. [PubMed ]
I have long been critical about afatinib, the “irreversible pan-HER inhibitor” from Boehringer-Ingelheim (BI) that is poised as a next generation EGFR inhibitor but actually has no real evidence that it’s more than a more toxic version of Tarceva or Iressa (gefitinib) as first line therapy for patients with an activating EGFR mutation and advanced NSCLC. with no clear added benefit. However, the LUX Lung 3 trial was conducted to conform to FDA gamesmanship and obtain a first line approval, and we anticipate that BI will win that approval. I have historically favored Tarceva because I see no evidence of greater benefit but worse side effects with afatinib, and unless mandated by payers, I don’t think we should reward gamesmanship that is about marketing rather than science. While I’d generally be happy to now have an official approval of Tarceva as first line therapy for people with advanced NSCLC and an activating EGFR mutation, this linking of the approval to a Roche test isn’t clearly better than what we have now, and it may well be inferior in many ways to “multiplex platforms” for broader molecular testing we hope to see more of in the next few years that would allow us to test for many relevant driver mutations at one time, with one sample. My sense is that this strategy by Roche is a commercially driven move that is a race to the bottom, bad for patients and for the science, and it represents a low point that underscores that when they purchased their partnership with Genentech, they diluted and sold away the soul and scientific credibility that the latter company had previously earned over time.
adenocarcinoma stage 1V AND Tarceva
She just started on a chemo treatment of Gemzar and will do 3 weeks on and 1 week off. Next week her oncologist will also have her start Tarceva. My sisters and I want to take her for a second opinion and would like to see if someone can recommend a hospital in the NY/NJ area that specializes in treating pancreatic cancer patients. Obviously we want to make sure that another dr agrees with the diagnosis and the treatment and also if they can offer other treatment options as well.
Based on animal data and its mechanism of action, erlotinib can cause fetal harm when administered to a pregnant woman
budindustrial.com.ua/форум/3-Хочу-заасфа...harmacokinetics#1226
We are offering erlotinib tablets. We supply erlonat tablets that prove to be an effective treatment for non-small cell lung cancer and pancreatic
Neoplasms Lung Diseases Respiratory Tract Diseases Erlotinib Therapeutic Uses Pharmacologic Actions Molecular Mechanisms of Pharmacological Action
12. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005; 2 :e73. [PubMed ]
Interestingly, we found that the 13-gene signature could not only predict response of patients to erlotinib, but could also discriminate primary (P) from metastatic (M) tumours, suggesting that the biological phenotypes underlying the signature were associated with both resistance to EGFR inhibition and metastatic behaviour ( Figure 1B ).
Brain lesions were well controlled by erlotinib with progression in the brain observed in only 4.8% of patients who had progressive disease.
Many translational and clinical cancer research efforts aim to identify biomarkers that may predict patients most likely to respond to treatment. The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) gefitinib and erlotinib have been studied extensively in clinical trials, 1 -8 and the association of EGFR-related biomarkers with EGFR-TKI clinical outcome has also been investigated.
Determine the relationship between erlotinib hydrochloride exposure (utilizing total and unbound erlotinib hydrochloride concentrations) and outcome, toxicity, and pharmacodynamic effects (upregulation of p27) in patients with different numbers of CA repeats.
mymusic.in.ua/forum/zvuki/2630-posted-by...pill-for-lung-cancer
ERLOTINIB IN CLINICAL TRIALS For its successful results in clinical trials of phase II against pancreatic, breast and lung cancers OSI-420 Desmethyl Erlotinib has proved itself very valuable medicine for their treatment. Erlotinib was also proved very remarkable against small cell lung carcinoma after the failure of Gefitinib [12] as cancer cells are known to have potential of adapting evasion strategies for ongoing therapeutic field hence shifted the paradigm from Gefitinib to Erlotinib triggered apoptosis in Gefitinib-resistant cell lines. Regarding pancreatic cancer, a clinical trial of phase II, Erlotinib promised better results and in case of advanced metastatic hepatocellular carcinoma caused its regression [13]. This drug has also found to exhibit good tolerance in clinical trials phase II of patients of elder lung cancer [14] as those patients were complaining about secondary complications generated by side effects of induction of drug. In OSI-420 lung cancer patients under phase III clinical trials, it has been reported that the there was an overall improvement of survival, side effects and low toxicity levels along with the regression in the volume of tumor. OSI-420 has experienced very remarkable success when used against patients lung cancer patients who have a known smoking history [16]. This medicine has also been used for pancreatic cancer patients under clinical trials phase 3 [17] and also as a combinational therapeutic tool in case of breast tumors [18-19] so now it is a great therapeutic horizon for above all three types of cancers.
To determine the toxicity of erlotinib in this setting. [ Time Frame: assessed every cycle (month) ] [ Designated as safety issue: Yes ]
To determine the feasibility, safety, and efficacy of erlotinib dose escalation in patients who do not develop a rash by cycle 1, day 15. [ Time Frame: assessed cycle 1, day 28, then every cycle (month) ] [ Designated as safety issue: Yes ]
PURPOSE: This phase I/II trial is studying the side effects and best dose of erlotinib when given together with radiation therapy and to see how well they work in treating young patients with newly diagnosed glioma.
Adverse events were observed in animal reproduction studies. Erlotinib crosses the placenta (Ji 2015; Jovelet 2015). Information related to the use of erlotinib in pregnancy is limited (Ji 2015; Rivas 2012; Zambelli 2008). Based on the mechanism of action, erlotinib may cause fetal harm if administered in pregnancy. Advise females of reproductive potential to use effective contraception during treatment and for at least 1 month after the last erlotinib dose.
www.actuals.ru/forum/7--/137509-posted-b...58-52-esmo-erlotinib
Drug: erlotinib [Tarceva] Drug: Placebo Drug: Onartuzumab [MetMAb]
regimens (10). Erlotinib was also superior to placebo with respect
The most common Grade 3-4 adverse event observed in patients treated with FOLOTYN was mucositis (23 percent). Other Grade 3-4 adverse events occurring in more than five percent (but less than 10 percent) of patients were fatigue (9 percent), dyspnea (6 percent), neutropenia (6 percent), thrombocytopenia (5 percent) and anemia (5 percent) in patients treated with FOLOTYN, and rash (8 percent), dyspnea (8 percent), anemia (8 percent) and fatigue (5 percent) in patients treated with erlotinib.
www.script-nn.ru/index.php/forum/раздел-...-bioavailability#443
Multivariate probabilistic sensitivity analysis (results of a 10 000-replication simulation). A . Gemcitabine v observation, B . Erlotinib v observation.
Most of the drugs in lung cancer score four, but Erlotinib, also used in this form of the disease, again scores one. Out of 14 drugs for bowel cancer, three score four but the rest all score less. For advanced breast cancer, Lapatinib scores five, but there are four drugs that score three or less, including Eribulin, which the National Institute for Health and Care Excellence (Nice) turned down but is paid for by the Cancer Drugs Fund. In melanoma (skin cancer), eight out of nine drugs score four.
laptop31.ru/forum/zayavi-o-sebe/843-post...-kidney-failure.html
In our experience, erlotinib was found slightly superior to gefitinib in objective response rate and disease control rate, but in terms of time to progression and survival after treatment, the two agents were statistically comparable.
The Docetaxel and Erlotinib Lung Cancer Trial (DELTA) is a multicenter, open-label, phase III study from Japan. Because gefitinib failed to show noninferiority to docetaxel in the V15-32 trial, we investigated the efficacy and tolerability of erlotinib versus docetaxel as second- or third-line treatment for EGFR -unselected patients with NSCLC.
van Tellingen O, Marchetti S, de Vries N, Zhao J, Buckle T, Beijnen JH, Schellens JH (2007) The impact of the ABC transporters P-gp and BCRP on the oral bioavailability and brain penetration of erlotinib using drug transporter knockout mouse models. Proc Am Assoc Cancer Res 48 (Suppl): 97 (abstract)
Spectroscopic studies on the interaction between erlotinib hydrochloride and bovine serum albumin.
The characteristics of the 25 patients are summarized in Table 1. Erlotinib was prescribed to 14 patients to manage LMC from NSCLC, and gefitinib was prescribed to 11 patients. The median age at diagnosis was 58 years (range, 44–70 years) in the erlotinib arm, and 49 years (range, 36–70 years) in the gefitinib arm. All patients in the erlotinib arm had adenocarcinoma; in the gefitinib arm nine patients (81.8%) had adenocarcinoma, and two patients (18.2%) had unspecified non–small-cell carcinoma. In the erlotinib arm, exon 21 point mutations and exon 19 deletional mutations existed in five patients each, whereas in the gefitinib arm, four patients (36.3%) had point-mutated exon 21 and three patients (27.3%) had deleted exon 19. Three patients (21.4%) who were prescribed erlotinib had wild-type EGFR . and none of the patients who received gefitinib had wild-type EGFR . Among patients who were included in the erlotinib arm, three patients had been using gefitinib and shifted to erlotinib on LMC occurrence; and another 11 patients received erlotinib as their first EGFR TKI after detection of LMC. In the gefitinib arm, six patients received gefitinib before and after LMC diagnoses without interruption, and another five patients were introduced to gefitinib as the start of the EGFR TKI.
I am sorry to hear about your father. Hopefully the chemotherapy will help. Has he been through chemo before? My husband has stopped the Tarceva for a few days and will go on a schedule of three days a week. We are hoping this will keep the side effects at a minimum. After six days without the pill he is finally starting to feel a little better. It was because the side effects were giving him so much pain that I searched the Internet for answers and posted here. Finally I called the drug company and they had some suggestions to help alleviate the pain. We were told that this pill is not chemotherapy but instead something that starves the cancer cells rather than killing them as in chemo. Of course in the process of killing cancer cells chemo also kills good healthy cells. That is why this was supposed to be "better" for him. We do know that a lump (lymph node) in his neck has disappeared while he was taking the drug. So hopefully that is a good sign. But I don't know how long he will be able to tolerate it if taking it less often makes the side effects come back again. Thanks for posting and good luck to your father. Jonio
mymusic.in.ua/forum/zvuki/2633-posted-by...-erlotinib-label-fda
Erlotinib Metabolic Imp.9
About Erlotinib generic
25. Wu YL, Lee JS, Thongprasert S, Yu CJ, Zhang L, Ladrera G, et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol (2013) 14 :777–86. doi:10.1016/S1470-2045(13)70254-7
Erlotinib is available in tablet form for oral administration.
Experimental: Arm II (tivantinib and erlotinib hydrochloride)